These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28427498)

  • 1. Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients
.
    Yamada E; Takagi R; Tanabe Y; Fujiwara H; Hasegawa N; Kato S
    Int J Clin Pharmacol Ther; 2017 Jul; 55(7):567-570. PubMed ID: 28427498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of abacavir, tenofovir, darunavir, and raltegravir in human plasma and saliva using liquid chromatography coupled with tandem mass spectrometry.
    Yamada E; Takagi R; Sudo K; Kato S
    J Pharm Biomed Anal; 2015 Oct; 114():390-7. PubMed ID: 26112927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
    Calza L; Danese I; Colangeli V; Manfredi R; Magistrelli E; Verucchi G; Conti M; Motta R; Viale P
    Infect Dis (Lond); 2015 Sep; 47(9):625-36. PubMed ID: 25875396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.
    Salama E; Hill L; Patel N; Best BM; Momper JD
    J Acquir Immune Defic Syndr; 2021 Dec; 88(4):389-392. PubMed ID: 34285156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.
    Vera JH; Jackson A; Dickinson L; Else L; Barber T; Mora-Peris B; Back D; Boffito M; Winston A
    HIV Clin Trials; 2015; 16(1):39-42. PubMed ID: 25777188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.
    Jackson A; Moyle G; Dickinson L; Back D; Khoo S; Taylor J; Gedela K; Abongomera G; Gazzard B; Boffito M
    Antivir Ther; 2012; 17(1):19-24. PubMed ID: 22267465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
    Cattaneo D; Minisci D; Cozzi V; Riva A; Meraviglia P; Clementi E; Galli M; Gervasoni C
    Antivir Ther; 2017; 22(4):353-356. PubMed ID: 28008867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.
    Pressiat C; Hirt D; Treluyer JM; Zheng Y; Morlat P; Naqvi A; Tran L; Viard JP; Avettand-Fenoel V; Rouzioux C; Meyer L; Cheret A;
    J Antimicrob Chemother; 2018 Apr; 73(4):1020-1024. PubMed ID: 29365125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.
    Lê MP; Valantin MA; Assoumou L; Soulie C; Le Mestre S; Weiss L; Yazdanpanah Y; Molina JM; Bouchaud O; Raffi F; Reynes J; Calvez V; Marcelin AG; Costagliola D; Katlama C; Peytavin G;
    Pharmacotherapy; 2019 Apr; 39(4):514-520. PubMed ID: 30815916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection.
    Calza L; Colangeli V; Magistrelli E; Bussini L; Conti M; Ramazzotti E; Mancini R; Viale P
    HIV Med; 2017 Aug; 18(7):474-481. PubMed ID: 28116848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.
    Di Yacovo MS; Moltó J; Ferrer E; Curran A; Else L; Gisslén M; Clotet B; Tiraboschi JM; Niubò J; Vila A; Zetterberg H; Back D; Podzamczer D
    J Antimicrob Chemother; 2015 May; 70(5):1513-6. PubMed ID: 25608583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
    Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
    HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of darunavir and etravirine in human peripheral blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry (LC-MS/MS), clinical application in a cohort of 110 HIV-1 infected patients and evidence of a potential drug-drug interaction.
    Belkhir L; De Laveleye M; Vandercam B; Zech F; Delongie KA; Capron A; Yombi J; Vincent A; Elens L; Haufroid V
    Clin Biochem; 2016 May; 49(7-8):580-6. PubMed ID: 26742721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Boosted darunavir, emtricitabine and tenofovir pharmacokinetics in sthe early and late postgastric bypass surgery periods.
    Baettig V; Courlet P; Delko T; Battegay M; Marzolini C
    AIDS; 2018 Aug; 32(13):1903-1905. PubMed ID: 30045058
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.
    Taburet AM; Sauvageon H; Grinsztejn B; Assuied A; Veloso V; Pilotto JH; De Castro N; Grondin C; Fagard C; Molina JM
    Clin Infect Dis; 2015 Oct; 61(8):1328-35. PubMed ID: 26105170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.
    Elliot ER; Amara A; Pagani N; Else L; Moyle G; Schoolmeesters A; Higgs C; Khoo S; Boffito M
    J Antimicrob Chemother; 2017 Jul; 72(7):2035-2041. PubMed ID: 28407075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients.
    Valade E; Bouazza N; Lui G; Illamola SM; Benaboud S; Treluyer JM; Cobat A; Foissac F; De Sousa Mendes M; Chenevier-Gobeaux C; Suzan-Monti M; Rouzioux C; Assoumou L; Viard JP; Urien S; Ghosn J; Hirt D
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abacavir/lamivudine fixed-dose combination with ritonavir-boosted darunavir: a safe and efficacious regimen for HIV therapy.
    Trottier B; Machouf N; Thomas R; Gallant S; Longpré D; Vézina S; Boissonnault M; Lavoie S; Legault D; Dion H; Nguyen VK
    HIV Clin Trials; 2012; 13(6):335-42. PubMed ID: 23195671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen.
    Meditz AL; Palmer C; Predhomme J; Searls K; Kerr B; Seifert S; Caraway P; Gardner EM; MaWhinney S; Anderson PL
    AIDS Res Hum Retroviruses; 2015 Oct; 31(10):1015-22. PubMed ID: 26059647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study.
    Lê MP; Soulié C; Assoumou L; Valantin MA; Duvivier C; Chas J; Ponscarme D; Marcelin AG; Calvez V; Katlama C; Peytavin G;
    J Antimicrob Chemother; 2015 Aug; 70(8):2418-20. PubMed ID: 25917348
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.